NCT03334812View on ClinicalTrials.gov

Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 18, 2017

Primary Completion Date

April 5, 2019

Study Completion Date

April 5, 2019

Conditions
Knee Cartilage Lesion
Interventions
BIOLOGICAL

LNA043

LNA043 Single dose

BIOLOGICAL

placebo to LNA043

placebo to LNA043 single dose

Trial Locations (2)

1090

Novartis Investigative Site, Vienna

1180

Novartis Investigative Site, Vienna

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY